Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Erratum
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lode, H.
Right arrow Articles by Allewelt, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lode, H.
Right arrow Articles by Allewelt, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 709-712
© 2002 The British Society for Antimicrobial Chemotherapy

Leading article

Role of newer fluoroquinolones in lower respiratory tract infections

H. Lode* and M. Allewelt

Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn, Central Clinic Emil von Behring, Zum Heckeshorn 33, 14109 Berlin, Germany

The impact of respiratory infections on inviduals in society is important and is growing as the population ages. Lower respiratory tract infections in particular are major causes of morbidity and mortality. These infections include acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia. Of the two conditions, AECB is more prevalent, occurring in 46% of the population over 65 years old in Germany, with an average of 2.4 acute exacerb- ations per patient each year. In the UK, chronic bronchitis causes 5% of deaths and is responsible for 28 million lost working days per year.

Community-acquired respiratory tract infections (RTIs) may be caused by Gram-positive organisms (predominantly Streptococcus pneumoniae), Gram-negative organisms (Haemophilus influenzae and Moraxella catarrhalis) and ‘atypical’ bacteria (e.g. Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae). In community-acquired pneumonia (CAP) pathogens, penicillin resistance . . . [Full Text of this Article]


   Footnotes
 

   References
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
H.-S. Park, H.-J. Kim, M.-J. Seol, D.-R. Choi, E.-C. Choi, and J.-H. Kwak
In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2261 - 2264.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. L. Baltch, L. H. Bopp, R. P. Smith, P. B. Michelsen, and W. J. Ritz
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes
J. Antimicrob. Chemother., July 1, 2005; 56(1): 104 - 109.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Leone, J. Albanese, E. Sampol-Manos, N. Simon, B. Lacarelle, B. Bruguerolle, and C. Martin
Moxifloxacin Penetration in Bronchial Secretions of Mechanically Ventilated Patients with Pneumonia
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 638 - 640.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. P. Johnson, C. L. Sheppard, S. J. Harnett, A. Birtles, T. Harrison, N. P. Brenwald, M. J. Gill, R. A. Walker, D. M. Livermore, and R. C. George
Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England
J. Antimicrob. Chemother., December 1, 2003; 52(6): 953 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Krausse and U. Ullmann
In Vitro Activities of New Fluoroquinolones against Campylobacter jejuni and Campylobacter coli Isolates Obtained from Humans in 1980 to 1982 and 1997 to 2001
Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2946 - 2950.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Gopal Rao, C. S. Mahankali Rao, and I. Starke
Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with {beta}-lactam-based therapy
J. Antimicrob. Chemother., March 1, 2003; 51(3): 697 - 701.
[Abstract] [Full Text] [PDF]